About the Event
Prescription for Progress brings together leaders across sectors working on technology and innovation to advance global health.
Through illuminating journalism, expert analysis, and a series of discussions, it features — and inspires — partnerships between innovators and the global health community that are essential to accelerating progress on health outcomes for all. In February 2022, we’ll gather once again- in person and online- to dive into learnings about global health partnerships over the past year. What’s working, what isn’t, and what’s next?
Since the first edition of Prescription for Progress in October 2018, there has been growing awareness of the role Silicon Valley, and technology and innovation more broadly, must play to move the needle in global health. The onset of the COVID-19 pandemic and the growing climate crisis have made it more critical than ever for cross-sector partnerships to leverage the power of technology in order to bridge gaps in global health. Innovation isn’t just found in the Bay Area, either, and is just as likely, if not more, to come out of Nairobi, Dhaka or Bogotá.
Prescription for Progress 2022 aims to connect the people at the center of these partnerships to bring solutions to scale in the COVID-19 response and long term recovery – and to accelerate progress on global health goals more broadly.
Topics will include:
• Technology and innovation in COVID-19 response
• Advancing progress on other health priorities during COVID-19
• Digital health tools: access, scale, trust
• Partnerships at the climate-health nexus
In a context where the amount of capital available to meet the Sustainable Development Goals by 2030 is scarce, investors for impact continuously work to capitalize on the resources available for leveraging and changing systems. Understanding performance gaps, impact needs, and the additionality of the impact created are essential to improving the effectiveness of the capital deployed.
Impact measurement and management (IMM) is deeply embedded into the DNA of investing for impact, as it drives decision-making throughout the whole investment journey, from the definition of investment strategy to the exit.
For this reason, EVPA has recently launched a report that highlights key questions to be asked and key elements to be considered to measure, but most importantly manage impact at each stage of the investment journey.
Download the report: https://evpa.eu.com/knowledge-centre/publications/navigating-impact-measurement-and-management
Sopact warmly welcomes Alessia Gianoncelli, Head of Knowledge Community and Market Development at @EVPA and one of the report’s authors, to discuss their main findings.
Do not miss the conversation. Join us.